Byondis B.v.
Clinical trials sponsored by Byondis B.v., explained in plain language.
-
New Antibody-Drug conjugate takes aim at Hard-to-Treat leukemia
Disease control OngoingThis early-stage trial tests a new drug called BYON4413 in 16 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have returned or not responded to standard treatments. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
New antibody combo tested in hard-to-treat cancers
Disease control OngoingThis early-phase trial tests a new drug called BYON4228, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and see if tumors shrink. Only 7 participants are enro…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New hope for tough lymphoma: first human trial of BYON4228 begins
Disease control OngoingThis early-stage study tests a new drug called BYON4228, alone or with another drug (rituximab), in people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has not responded to previous treatments. The main goal is to check safety and find the right dose. Only 17 pa…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated May 26, 2026 11:07 UTC